Future studies will determine whether rebalancing VEGFR-1 signaling events may delay senescence, inflammation, and nanomechanical alterations of ECs, which may be beneficial in age-related disease models, including AD and vascular dementia. Here, FLT1 is linked to Alzheimer disease.